Propranolol given by intravenous pump to prevent pneumonia after bleeding in the brain
Tests propranolol by intravenous pump in people with bleeding in the brain.
Plain-language title generated from the registry record
Registry title: An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH
Key facts
- Where
- Xi'an, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 80 years old?
Source: NCT07528235, who can take part
Where in China
- Department of Neurosurgery , Tangdu Hospital, Fourth Military Medical UniversityXi'an, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tang-Du Hospital
- Trial code
- NCT07528235
- Record updated
- 14 April 2026
- Original description
This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.Read full original descriptionShow less
An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing Stroke-Associated Pneumonia of Intravenous Pump-Delivered Propranolol in Patients With Intracerebral Hemorrhage
This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.
Inclusion: Patients aged > 18 and ≤ 80 years of age; Can be treated with the study drug within 24 h of symptom onset; No fever or infection was observed upon admission; NIHSS score ≥10; Supratentorial parenchymal haematoma (≥10 mL); GCS score ≥ 6; Patients or their family members sign informed consent forms.
Exclusion: Previous disability with pre-ICH mRS score ≥ 2; Previous use (within 1 month) of β-blockers or reserpine; Infections within the last 4 weeks; Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes; Brainstem hemorrhage; Severe or acute heart failure; Heart rate < 65 beats/min; Known to be allergic to propranolol; Severe liver or renal insufficiency; History of malignant tumors; Use of antibiotics within the last 2 weeks; Known pre-ICH dysphagia; Life expectancy less than 14 days; Death appeared imminent; Pregnancy or within 30 d of delivery; Bronchial asthma or COPD; Cardiogenic shock; Degree II-III atrioventricular blocks; Currently participating in other interventional clinical trials; Currently, immunosuppressants and immunotherapies are being administered.